News

Antioxidants may help improve CF exercise capacity: Study

High blood sugar can impair the ability to utilize oxygen for energy with cystic fibrosis (CF), which may explain why exercise can be especially tiring for those with the disease, a new study shows. Researchers think the biological mechanism responsible for this phenomenon is that high blood sugar can…

CFF funding TB Alliance to advance potential NTM therapy

The Cystic Fibrosis Foundation is funding up to $3.9 million to TB Alliance to conduct preclinical studies of a compound that could be used to treat infections caused by nontuberculous mycobacteria (NTM) in people with cystic fibrosis (CF). These infections often require antibiotic treatment for more…

Kaftrio helped fight P. aeruginosa bacteria

Taking Kaftrio, a combination of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., for up to 24 weeks can make signs of inflammation go down in people with cystic fibrosis (CF), and help get rid of Pseudomonas aeruginosa bacteria. That’s according to data from a…

Orkambi’s anti-inflammatory benefits seen in a real-world study

Beyond improving lung function, Orkambi (ivacaftor/lumacaftor) has potent anti-inflammatory benefits that may limit immune-related lung damage in people with cystic fibrosis (CF), according to a real-world study. Researchers found that one year of treatment significantly reduced the levels of pro-inflammatory signaling molecules in the bloodstream and airways of…